The effect of anticancer treatment on cancer patients with COVID‐19: A systematic review and meta‐analysis

Liu, Hanqing; Yang, Dan; Chen, Xinyue; Sun, Zhihong; Zou, Yutong; Chen, Chuang; Sun, Shibin

doi:10.1002/cam4.3692

Cited by 48 publications

(61 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results indicated a high degree of similarity among the two treatment groups, with no significant difference appreciated between these groups with respect to ED utilization, ED imaging, indications and duration of hospitalization, and mortality. These results are supported by a recent study published by Liu et al, in which antineoplastic therapy did not result in any difference in disease severity or mortality [ 15 ]. Additionally, despite the concern about treatment-related complications, our study did not reveal any imaging findings or hospitalizations attributed primarily to cancer treatment.…”

Section: Discussionsupporting

confidence: 85%

COVID-19 infection in the cancer population: a study of emergency department imaging utilization and findings

et al. 2021

View full text Add to dashboard Cite

Purpose To analyze emergency department (ED) computerized tomography (CT) utilization in cancer patients with coronavirus disease 2019 (COVID-19). Methods A retrospective chart review was performed to identify cancer patients who received COVID-19 diagnosis within the single healthcare system and presented to the ED within 30 days of COVID-19 positive date between May 1 and December 31, 2020. Results In our 61 patients, the mean age was 72.5 years old, with 34% of patients ( n = 21) on active cancer therapy and 66% ( n = 40) on surveillance only. Most patients ( n = 53) received their COVID-19 diagnosis within the ED, with 8 patients diagnosed prior to initial ED visit. The most common CT studies ordered within the ED were CT chest ( n = 25), CT abdomen/pelvis (A/P) ( n = 20), CT head ( n = 8), and CT chest/abdomen/pelvis (C/A/P) ( n = 7). COVID-19 findings were present on 33 scans, findings of worsening malignancy on 12 scans, and non-COVID non-cancer findings on 9 scans. Significant differences in CT severity score ( p = 0.0001), indication for hospitalization ( p = 0.026), length of hospitalization ( p = 0.004), interventions (remdesivir, mechanical ventilation, and vasopressor support) while hospitalized ( p < 0.05), and mortality ( p = 0.042) were found between the prior diagnosis and ED diagnosis groups. No such differences were found between the active treatment and surveillance groups. Conclusion ED CT imaging findings in patients with cancer and COVID-19 are predominantly related to COVID-19 infection, rather than cancer history or anti-cancer therapy status.

show abstract

Section: Discussionsupporting

confidence: 85%

COVID-19 infection in the cancer population: a study of emergency department imaging utilization and findings

et al. 2021

View full text Add to dashboard Cite

show abstract

“…As a result, they concluded that cancer surgery can be performed without higher risks of either severe events or death in patients with cancer along with COVID-19. We are pleased to see such work, as this is an important topic, with similar results published in other recent meta-analyses [ 2 , 3 ]. Because SARS-CoV-2 infections have been shown to worsen outcomes in patients with cancer compared with non-cancer patients, additional data are needed to examine the effect of cancer treatments on infection.…”

supporting

confidence: 74%

Re: A systematic review and meta-analysis: The effect of active cancer treatment on severity of COVID-19

Zou

Huang

et al. 2021

European Journal of Cancer

View full text Add to dashboard Cite

“…A cohort study on COVID-19 in breast cancer patients showed that hypertension and age (> 70 years) were associated with a higher risk of intensive care unit admission, death, or both [ 16 ]. With respect to tumor type, chemotherapy for patients with hematological malignancies has been reported to lead to higher mortality in COVID-19 [ 4 ]. Furthermore, there has been a case report describing severe COVID-19 virus reactivation following the resumption of chemotherapy for B cell acute lymphoblastic leukemia [ 7 ].…”

Section: Discussionmentioning

confidence: 99%

“…Some reports suggest that cancer patients could be at an increased risk of developing COVID-19-related complications, and many oncological societies have issued guidelines to assist clinical decisions and management during this crisis [ 1 , 2 ]. Many studies have verified the effect of recent anti-cancer treatment in patients with COVID-19; however, the results remain controversial [ 3 , 4 ]. Moreover, no study has evaluated the risk for post-COVID-19 patients who resumed their anti-cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

Chemotherapy resumption in breast cancer patient after COVID-19

et al. 2021

View full text Add to dashboard Cite

Background While many studies have verified the effect of recent anti-cancer treatment in patients with COVID-19, there are no data on the optimal time for cancer treatment resumption, as well as the safety of chemotherapy in COVID-19 patients. As many cancer patients are recovering from COVID-19, there is an urgent need for reliable clinical information. Herein, we report a case of invasive ductal carcinoma in which we were able to successfully resume chemotherapy after infection with SAR-CoV-2. Case presentation The patient was a 38-year-old non-smoking Japanese woman with no significant medical history. She had fever on days 5 and 6 of her second course of adjuvant FEC therapy, and on day 7, she tested positive for SARS-CoV-2 by RT-PCR. She was hospitalized for 11 days. We resumed the therapy on day 25 after discharge, as she had no remaining clinical symptoms. The patient completed four courses of the initial chemotherapy without any major adverse events nor the recurrence of COVID-19, and subsequently completed four courses of docetaxel as her second regimen therapy. Conclusions Evaluating the risk for each patient is essential when resuming anti-cancer therapy in cancer patient’s post-COVID-19.

show abstract

The effect of anticancer treatment on cancer patients with COVID‐19: A systematic review and meta‐analysis

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 48 publications

References 60 publications

COVID-19 infection in the cancer population: a study of emergency department imaging utilization and findings

COVID-19 infection in the cancer population: a study of emergency department imaging utilization and findings

Re: A systematic review and meta-analysis: The effect of active cancer treatment on severity of COVID-19

Chemotherapy resumption in breast cancer patient after COVID-19

Contact Info

Product

Resources

About